EUVIMEDEUVIMED entdecken
Crossref

Molecular profile and peripheral markers of neurodegeneration in patients with Niemann-Pick type C: Decrease in Plasminogen Activator Inhibitor type 1 and Platelet-Derived Growth Factor type AA

Tatiane Grazieli Hammerschmidt, Marisa Encarnação, Jéssica Lamberty Faverzani, Franciele de Fátima Lopes, Fabiano Poswar de Oliveira, Carolina Fischinger Moura de Sousa, Isaura Ribeiro, Sandra Alves, Roberto Giugliani, Carmen Regla Vargas

Archives of Biochemistry and Biophysics · 2023

DOI: 10.1016/j.abb.2023.109510 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Biochemistry and Biophysics, 2023. Verfasst von Tatiane Grazieli Hammerschmidt und 9 weiteren Autor:innen. Beteiligte Einrichtung: Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. Hauptthemen laut MEDLINE: Brain-Derived Neurotrophic Factor, Niemann-Pick Disease, Type C. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 62 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Niemann-Pick type C1 (NPC1) is a fatal inherited disease, caused by pathogenic variants in NPC1 gene, which leads to intracellular accumulation of non-esterified cholesterol and glycosphingolipids. This accumulation leads to a wide range of clinical manifestations, including neurological and cognitive impairment as well as psychiatric disorders. The pathophysiology of cerebral damage involves loss of Purkinje cells, synaptic disturbance, and demyelination. Miglustat, a reversible inhibitor of glucosylceramide synthase, is an approved treatment for NPC1 and can slow neurological damage. The aim of this study was to assess the levels of peripheric neurodegeneration biomarkers of NPC1 patients, namely brain-derived neurotrophic factor (BDNF), platelet-derived growth factors (PDGF-AA and PDGF-AB/BB), neural cell adhesion molecule (NCAM), PAI-1 Total and Cathepsin-D, as well as the levels of cholestane-3β,5α,6β-triol (3β,5α,6β-triol), a biomarker for NPC1. Molecular analysis of the NPC1 patients under study was performed by next generation sequencing (NGS) in cultured fibroblasts. We observed that NPC1 patients treated with miglustat have a significant decrease in PAI-1 total and PDGF-AA concentrations, and no alteration in BDNF, NCAM, PDGF-AB/BB and Cathepsin D. We also found that NPC1 patients treated with miglustat have normalized levels of 3β,5α,6β-triol. The molecular analysis showed four described mutations, and for two patients was not possible to identify the second mutated allele. Our results indicate that the decrease of PAI-1 and PDGF-AA in NPC1 patients could be involved in the pathophysiology of this disease. This is the first work to analyze those plasmatic markers of neurodegenerative processes in NPC1 patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain-Derived Neurotrophic FactorNiemann-Pick Disease, Type CHumansPlasminogen Activator Inhibitor 1Platelet-Derived Growth FactorBiomarkersBecaplermin1-Deoxynojirimycin

Stichwörter der Autor:innen

Lysosomal storage diseasesMiglustatNeurodegenerationNext generation sequencingNiemann-Pick type C

Substanzen

Brain-Derived Neurotrophic FactorPlasminogen Activator Inhibitor 1Platelet-Derived Growth FactorBiomarkersBecaplerminplatelet-derived growth factor Amiglustat1-Deoxynojirimycin

Autor:innen und Institutionen

  • Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
  • Research & Development Unit, Human Genetics Department, National Institute of Health Doutor Ricardo Jorge, Porto, Portugal.
  • Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil; Serviço de Genética Médica, HCPA, Porto Alegre, Brazil.
  • Serviço de Genética Médica, HCPA, Porto Alegre, Brazil.
  • Unidade de Bioquímica Genética, Centro de Genética Médica, Centro Hospitalar Universitário do Porto, Porto, Portugal; Unit for Multidisciplinary Research in Biomedicine, ICBAS-UP, Porto, Portugal; Espero Centro Referênc…
  • Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil; Serviço de Genética Médica, HCPA, Porto Alegre, Brazil. Electronic address: crvargas@hcpa.edu.br.

Zitieren

APA

Hammerschmidt, T. G., Encarnação, M., Lamberty Faverzani, J., de Fátima Lopes, F., Poswar de Oliveira, F., Fischinger Moura de Sousa, C., Ribeiro, I., Alves, S., Giugliani, R., & Regla Vargas, C. (2023). Molecular profile and peripheral markers of neurodegeneration in patients with Niemann-Pick type C: Decrease in Plasminogen Activator Inhibitor type 1 and Platelet-Derived Growth Factor type AA. Archives of Biochemistry and Biophysics. https://doi.org/10.1016/j.abb.2023.109510

Vancouver

Hammerschmidt TG, Encarnação M, Lamberty Faverzani J, de Fátima Lopes F, Poswar de Oliveira F, Fischinger Moura de Sousa C, et al. Molecular profile and peripheral markers of neurodegeneration in patients with Niemann-Pick type C: Decrease in Plasminogen Activator Inhibitor type 1 and Platelet-Derived Growth Factor type AA. Archives of Biochemistry and Biophysics. 2023. doi:10.1016/j.abb.2023.109510

BibTeX
@article{Hammerschmidt2023,
  author = {Hammerschmidt, Tatiane Grazieli and Encarnação, Marisa and Lamberty Faverzani, Jéssica and de Fátima Lopes, Franciele and Poswar de Oliveira, Fabiano and Fischinger Moura de Sousa, Carolina and Ribeiro, Isaura and Alves, Sandra and Giugliani, Roberto and Regla Vargas, Carmen},
  title = {Molecular profile and peripheral markers of neurodegeneration in patients with Niemann-Pick type C: Decrease in Plasminogen Activator Inhibitor type 1 and Platelet-Derived Growth Factor type AA},
  journal = {Archives of Biochemistry and Biophysics},
  year = {2023},
  doi = {10.1016/j.abb.2023.109510}
}
Kostenlos starten →